- PAM Theragnostics and FyoniBio have entered into a collaboration to develop a manufacturing process for peptidylglycine alpha-amidating monooxygenase (PAM), a candidate being developed for the prevention of Alzheimer’s disease.
- FyoniBio will use its CHOnamite® cell line development platform to identify and develop the most suitable production cell line for the PAM-based therapy candidate.
PAM Theragnostics, a German life sciences start-up, has entered into a collaboration with FyoniBio to develop a manufacturing process for peptidylglycine alpha-amidating monooxygenase (PAM), a glycoprotein being investigated as a potential therapy for the prevention of Alzheimer’s disease.
Under the agreement, FyoniBio will apply its CHOnamite® cell line development platform to support production process development. The platform includes multiple host cell lines that can be screened to identify the most suitable production system for achieving the required quality and yield of PAM Theragnostics’ drug candidate.
The collaboration is intended to establish a scalable manufacturing process as PAM Theragnostics advances its enzyme-replacement therapy for patients with PAM deficiency toward clinical development. According to the companies, PAM is an enzyme associated with maintaining brain health and forms the basis of the therapeutic approach under development.
“We are proud that PAM Theragnostics has chosen FyoniBio as its trusted partner, underscoring that our highly potent and well-established CHOnamite® cell line platform is ideally suited for complex protein formats.”
Dr. Lars Stöckl, Managing Director of FyoniBio
The companies stated that the partnership combines PAM Theragnostics’ therapeutic development efforts with FyoniBio’s expertise in cell line and process development. The work will focus on creating a robust production process capable of supporting future clinical development activities for the PAM-based therapy candidate.
